Zimbabwe has turned down a major US health deal worth $367m (£272m) spanning five years over the United States' request for confidential data.
The decision came to light following a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman later clarified that the US was seeking genetic material for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more talks to reach a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
This rejection comes after a similar case in Kenya, where a court halted a related deal with the US after legal challenges were raised about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
As per statements, 16 African countries have so far agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be available to our citizens if a new health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems already set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to manage future global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We are open to further discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts stated it recognised the government's concerns, but recommended that talks should continue since much of the nation's Aids initiatives relied on international support.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation underscores the ongoing tensions between receiving much-needed international aid and protecting a country's data in an increasingly data-driven world.